On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- Barton expanding access with new technologyon July 8, 2021 at 5:35 am
Barton Health continues to innovate with medical imaging technology, investing in the latest equipment that enhances services, expands care, and improves the patient experience.
- Understanding the myths and facts about degenerative disc diseaseon July 8, 2021 at 3:00 am
Gordon explains that degenerative disc disease (DDD) is a normal part of aging in the spine that begins in our 20’s. In fact, the term DDD itself, he said, gives the wrong impression. “It’s not a ...
- SeaSpine Announces FDA 510(k) Clearance of 7D Surgical Percutaneous Spine Module for Minimally Invasive Surgeryon July 7, 2021 at 8:05 am
SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510 (k) clearance of its ...
- TheraVet Provides Its Half-year Operational Update Of 2021on July 7, 2021 at 2:30 am
TheraVet S.A. (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, provides tod ...
- New study pinpoints two separate mutation near GDF5 gene for osteoarthritis, hip dysplasiaon July 6, 2021 at 12:34 pm
Terence D. Capellini has been interested in how joints work for almost three decades. Part of it is due to personal experience, having sustained several joint injuries as a college ice hockey player ...
- Beyond CAR-T: New Frontiers in Living Cell Therapieson July 6, 2021 at 8:30 am
Taking a page from computer engineers, biologists are trying their hands at programming cells – by building DNA circuits to guide their protein-making machinery and behavior.
- Neurosurgery Surgical Power Tools Market Projected to Grow at a CAGR of 4.4% During the Forecast Period 2021-2026on July 5, 2021 at 11:15 am
Neurosurgery Surgical Power Tools Market” The Increasing Acceptance of Minimally Invasive Neurosurgeries for a Variety of Procedures, Including Brain ...
- Joint Guard 360 Reviews – Does It Really Work for Joint Pain?on July 3, 2021 at 1:28 pm
Joint Guard 360 is a product meant to improve joint and bone pain. Discover if its right for you with these reviews.
- SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Educationon July 2, 2021 at 8:02 am
The SI-BONE SImulator module is an innovative training simulation system that provides surgeons a next generation platform to learn new SI-BONE sacropelvic procedures, sharpen existing surgical ...
via Bing News